Thursday, 27 June 2019,DAC Beachcroft, London


Are you looking to network with others in this sector and speak with investors interested in your industry?

Master Investor ‘in focus’ is our series of topical bespoke events, here we turn our focus to the European Cannabis & CBD Market and present the opportunities for growth and investment within this sector.

Master Investor will explore the controversial yet evolving changes companies within this sector are facing and how to effectively communicate this change and its benefits to potential investors.

Expect an engaging evening that will explain the challenges and opportunities in this sector, including the law around Cannabis and investing, the science behind the medical benefits and of course, key investment considerations and strategies.


Highlighting the growth and changes within this industry is fundamental for obtaining the best investments. Master Investor in focus: Investing in European Cannabis and CBD Market will allow you to:

Learn about the exciting new changes in legalisation and drug research from highly innovative companies and what investors really think.

Put your own business or personal investment questions to the experts, in an exclusive panel discussion, for thought-provoking experiences and insights.

Network with private investors and leading experts within the Cannabis sector.


1 November 2018
09:30- 17:00

A packed programme of presentations – all delivered by scientists and business leaders at the cutting edge of the field – ensures you’ll leave the event with valuable learning points to help build your longevity investment portfolio.

  • The rejuvenation biotech boom is imminent, and it will dwarf the dotcom boom
    Dr Aubrey de Grey – Chief Science Officer, SENS Research Foundation
  • The prospects for treatments for ageing: a biogerontologist’s view
    David Gems – Professor of Biogerontology, Institute of Healthy Ageing, University College London
  • Strategies to tackle senescent cells in developing anti-ageing therapies
    Professor Lynne S. Cox – Professor of Biogerontology, University of Oxford
  • Where do longevity de-risking, investment and Usain Bolt converge?
    Jennifer Donohue – Founder, Algorithm and Extremal Consulting Ltd
  • Regenerative medicine and ageing: Targeting markets in age-related chronic degenerative disease
    Mike West – CEO, AgeX Therapeutics
  • Ageing interventions get human
    Dr Brian Kennedy – Director, Centre for Healthy Ageing
  • Living healthily for a long life and in robust financial shape
    Jim Mellon – Chairman, Juvenescence Limited
  • Investing to cure the diseases of ageing and extend healthy life
    James Peyer – Managing Partner, Apollo Ventures
  • AI for longevity biotechnology
    Polina Mamoshina – Senior Researcher, Insilico Medicine
  • Opportunities and challenges: The path to turn the science into commercial reality
    Panel discussion – Chronomics, Brain Patch, Cleara, Insilico
  • Translating the science of ageing into consumer products
    Dr Nichola Conlon – CEO, Nuchido



Victor Hill


Victor is a financial economist, consultant, trainer and writer, with extensive experience in commercial and investment banking and fund management. His career includes stints at JP Morgan, Argyll Investment Management and World Bank IFC.

Jonathan Deverill

DAC Beachcroft

Jonathan is one of the leading medical cannabis lawyers in the UK with over 20 years’ experience in corporate and commercial work, including IPOs (AIM, UK Official List and Toronto Stock Exchange) and other securities offerings, M&A, takeovers and joint ventures. Over the years Jonathan has been involved in a significant number of cross-border transactions, particularly in the Canadian market and he is one of the first specialised commercial lawyers in the field of medical cannabis and CBD.

About DAC Beachcroft:

The DAC Beachcroft Medical Cannabis team supports both domestic and overseas clients on a variety of matters in this fast-evolving, entrepreneurial sector. Corporate Partner Jonathan Deverill leads the team, with expertise drawn from across the firm’s health, public law, corporate, life sciences and product liability teams. DACB counts amongst its clients in this sector several well-known Canadian-listed companies, certain UK-listed companies, and a number of start-up businesses operating both in the UK and elsewhere, as well as investment firms and stockbrokers.

Dr. Anna Morera Leralta

Wuhan General Group

Dr. Anna Morera Leralta (Dr. Anna) is a doctor of Medicine and Surgery, specializing in integrative medicine and treating patients with medical cannabis. She works at her clinical practice as well as gives educational talks and online consultations.

Dr. Anna graduated from the Autonomous University of Barcelona (Spain) in 2018. She completed her medical degree in the Hospital Vall d’Hebron (Barcelona, Spain) and the Hôpital Central (Nancy, France). In parallel to her studies, Dr. Anna has participated in several internships and voluntary services globally, in places like San Francisco (CA, United States), Bangkok (Thailand), London (England), Paris (France) and Lausanne (Switzerland). She has worked hand-in-hand with well-known physicians and professionals of the Health-Biotech sector. She’s been awarded with numerous awards of excellence and scholastic scholarships. Dr. Anna has been inspired by her research in the field of molecular science to create a CBD-infused nutraceutical line. Dr. Anna backs CBD research and confidently recommends the use of CBD cosmetics and health products.

About Wuhan General Group:

Wuhan General Group (China), Inc. through its wholly-owned subsidiary “MJ MedTech, Inc.” is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the “Dr. AnnaRx” brand.

In addition, Wuhan’s new division “M2BIO” aims to explore and develop additional indications for psilocybin new therapies that will help patients who suffer from mental illness.

Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies.

Wuhan General Group (China), Inc. is a public company trading on the OTC Pink under the ticker symbol: WUHN.

Phillip Shum

Canadian Securities Exchange

Speaker and company details coming soon.


Victor Hill


Victor is a financial economist, consultant, trainer and writer, with extensive experience in commercial and investment banking and fund management. His career includes stints at JP Morgan, Argyll Investment Management and World Bank IFC.

Melissa Sturgess

CEO, Ananda Developments

Melissa Sturgess holds a BSc and an MBA and has more than 20 years of experience as a director of UK and Australian Stock Exchange quoted companies, mainly involved in the acquisition, structuring and financing of natural resources deals across Africa. Miss Sturgess commenced her career in Australia as a member of the Executive Committee of Aquarius Platinum Limited, one of the first Australia/UK dual listed companies and a miner of platinum in South Africa and Zimbabwe. She was also founding director of Sylvania Resources Limited and a number of other companies operating in the metals and mining sector throughout Africa and listed on the AIM Market in London. Miss Sturgess relocated to London in 2006 and during her career has raised significant amounts of capital. She was a key driver in the successful recapitalisation of Messaging International plc during 2016 which subsequently changed its name to SigmaRoc Plc, acquired a building materials business via a reverse takeover and raised £50 million from a range of investors in the Channel Islands and the UK. Miss Sturgess’ interest in the cannabis sector started in 2017 with a trip to Israel to review the Medicinal Cannabis research that is happening in that country. She subsequently founded Ananda Developments to invest in the sector and is its largest shareholder.

About Ananda Developments:

The Company’s investment strategy is to invest in companies, projects or products that are either progressing medicinal or therapeutic Cannabis research and development, or are developing or have already developed, products that contain Cannabis derived cannabinoids and require funding to progress work plans or commercialise products. Ananda will look to invest in companies or projects in Israel, Canada and the Netherlands.

Ed McDermott

FastForward Innovations

Ed McDermott a former investment banker, has 15 years’ experience in the management, financing and development of growth companies internationally. He has broad experience in a number of sectors including medicinal cannabis, natural resources, technology and financial services.

Ed is currently Executive Director and UK Managing Director of EMMAC Life Sciences Ltd and a Non-Executive Director of Emmerson Plc listed on the London Stock Exchange (Standard Listing). He has held a number of Executive and Non Executive roles with public and private companies.

About FastForward Innovations:

FastForward Innovations invests in companies developing emerging technologies that will shape the future.

We are principally focused on early stage investments and aim to bring investment opportunities often reserved for venture capital firms to the average investor. Dedicated to the success of each of our portfolio companies, we believe that their products and services will be transformative.

Alongside investments in FinTech, BioTech, EdTech and Gaming, we are the only AIM company currently invested in a medically focused Cannabis business, having successfully invested in EMMAC Life Sciences in March 2019. This investment follows our success in Nuuvera Inc. in 2017/18.

Leon Giese

CEO, BioDelta

Leon Giese is the co-founder and CEO of South African based BioDelta, an industry leader in design, manufacturing and distribution of health supplements internationally. He consults to the pharma industry on product development and supply chain optimisation. He has a Business Degree (UCT), Packaging Technology Diploma (CPUT) and Coaching Diploma (TCC). He is passionate about helping people and organisations to reach their full potential.

About BioDelta

BioDelta are a contract manufacturing company that is changing the way manufacturing is perceived in the value chain of getting products to the consumer. BioDelta bring logical thought into the areas of policies, procedures and measurements within the value chain where we have influence or control. BioDelta partner with you to focus on key areas that deliver the most impact for the most important part of the value chain – the consumer..


Get in touch today for a no obligation consultation from our Head of Business Development, Amanda Taylor. You can also reach Amanda on +44 (0) 20 7164 6414.



DAC Beachcroft
25 Walbrook


Thursday 27 June 2019, 18:00 – 21:30

For 50% off tickets use code WEB50B – limited availability